Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
Tempus AI
Actym Therapeutics, Inc.
Bolt Biotherapeutics, Inc.
Elevation Oncology
Aminex Therapeutics, Inc.
Merck Sharp & Dohme LLC
Pfizer
CytomX Therapeutics
Fate Therapeutics
Hoffmann-La Roche
University of Iowa
Advaxis, Inc.
Rubius Therapeutics
Tocagen Inc.
CureOne
University Health Network, Toronto
Vanderbilt-Ingram Cancer Center